Back to search results
NCT05873192

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Recruiting
PHASE2Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~30 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:ADTEnzalutamideTalazoparibDegarelixLuprolide

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured over Through study completion; an average of 1 year.

Conditions

Prostate Cancer

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Amado Zurita-Saavedra, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Amado Zurita-Saavedra, MD
[email protected]
(713) 563-6966
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0Through study completion; an average of 1 year.